Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients.

Co-processing an active pharmaceutical ingredient (API) with a low Tg excipient has been previously reported to be an effective strategy for preventing drug amorphisation on milling. This technique relies on the ability of the excipient to form a molecular dispersion with the amorphous API during the milling process. The presence of the excipient within the amorphous phase induces a reduction of the Tg. Hence, the molecular dispersion becomes less stable than the amorphous API alone and recrystallises upon milling. The objective of this study was to develop a screening method for the selection of suitable excipients to prevent amorphisation, based on two criteria: the Tg of the excipient and the solubility of the excipient in the amorphous API. The ability of the excipients to induce Tg reduction was first assessed by measuring the Tg of the amorphous composite by thermal analysis and comparing it with that of the pure API (griseofulvin). A predicted ability for mitigation of amorphisation upon milling was then deduced from these observations for each excipient and assessed against experimental results. The same excipients were then studied with regard to their expected solubility in another amorphous API (budesonide) by Hildebrand solubility parameter calculations in order to evaluate their capacity to form an amorphous composite with the drug. The predicted effects of the excipients on comilling were compared with the amorphous content of the processed API. The screening method as applied to both APIs showed good agreement with the experimental results and were shown to be efficient for the selection of the most appropriate excipient. This approach revealed that the two key parameters involved are the Tg of the excipient and the ability of the API to form an amorphous molecular dispersion with the excipients. This work confirms and completes our previously published results on the mitigation of the amorphisation by comilling with low Tg excipients and constitutes the first report of the use of a polymeric additive for this purpose.

[1]  M. Descamps,et al.  Solid state amorphization of pharmaceuticals. , 2008, Molecular pharmaceutics.

[2]  V. Caron,et al.  Investigation of the capacity of low glass transition temperature excipients to minimize amorphization of sulfadimidine on comilling. , 2013, Molecular pharmaceutics.

[3]  L. Carpentier,et al.  Solid-state vitrification of crystalline griseofulvin by mechanical milling. , 2012, Journal of pharmaceutical sciences.

[4]  M. Descamps,et al.  A new protocol to determine the solubility of drugs into polymer matrixes. , 2013, Molecular pharmaceutics.

[5]  M. Descamps,et al.  Ordering and disordering of molecular solids upon mechanical milling: the case of fananserine. , 2008, Journal of pharmaceutical sciences.

[6]  Anne Marie Healy,et al.  Reducing mechanical activation-induced amorphisation of salbutamol sulphate by co-processing with selected carboxylic acids. , 2013, International journal of pharmaceutics.

[7]  V. Pokharkar,et al.  Development, characterization and stabilization of amorphous form of a low Tg drug , 2006 .

[8]  R. F. Fedors,et al.  A method for estimating both the solubility parameters and molar volumes of liquids , 1974 .

[9]  S. Chan,et al.  Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives. , 2010, Journal of pharmaceutical sciences.

[10]  Bruno C. Hancock,et al.  Characteristics and significance of the amorphous state in pharmaceutical systems. , 1997, Journal of pharmaceutical sciences.

[11]  V. Caron,et al.  Formation of budesonide/α-lactose glass solutions by ball-milling , 2006 .

[12]  P York,et al.  Solubility parameters as predictors of miscibility in solid dispersions. , 1999, Journal of pharmaceutical sciences.

[13]  V. Caron,et al.  Transformation of pharmaceutical compounds upon milling and comilling: the role of T(g). , 2007, Journal of pharmaceutical sciences.

[14]  A. Bansal,et al.  Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. , 2006, Journal of pharmaceutical sciences.

[15]  M. Gallarate,et al.  Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. , 2003, International journal of pharmaceutics.

[16]  L Yu,et al.  Amorphous pharmaceutical solids: preparation, characterization and stabilization. , 2001, Advanced drug delivery reviews.

[17]  S. Nail,et al.  The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. , 1998, Journal of pharmaceutical sciences.

[18]  A. Healy,et al.  Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation. , 2014, International journal of pharmaceutics.

[19]  Jung Min Park,et al.  Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry. , 2002, International journal of pharmaceutics.